Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066230 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
A Phase 3 study, sponsored by Kodiak Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 253
- Enrollment target
NCT05066230 is a Phase 3 study that was terminated before completion, run by Kodiak Sciences. The registered enrollment target is 253 participants.
The verdict
NCT05066230, a Phase 3 study, was terminated before completion, sponsored by Kodiak Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 253 participants
- Enrollment target
Study Summary
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
Interventions
- OTHER Sham injection
- DRUG KSI-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05066230
The ClinicalTrials.gov registry entry for NCT05066230 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kodiak Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham injection is the first listed.
NCT05066230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05066230 about?
NCT05066230 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)". This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
What is the current status of trial NCT05066230?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 253 participants. The study started on 2021-09-07. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05066230?
The interventions under investigation include: Sham injection (OTHER), KSI-301 (DRUG).
Who is sponsoring clinical trial NCT05066230?
This trial is sponsored by Kodiak Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.